恒瑞医药：一项注射用SHR-1826联用其他药物临床研究获批

Core Insights - The company, Heng Rui Medicine, announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have received approval from the National Medical Products Administration for clinical trials of SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] Group 1 - The clinical trials will focus on the safety, tolerability, and efficacy of SHR-1826 in combination with other anti-tumor treatments for patients with solid tumors [1] - The trials will be multi-center and open-label, categorized as Phase I/II [1]